Drug Trial Radar · NCT00223925
Maribavir for Prevention of CMV After Stem Cell Transplants
Last checked: Nov 19, 2026Latest source record: May 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Oct 28, 2004
Primary completion
Apr 5, 2006
Study completion Apr 5, 2006
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.
Conditions
- Cytomegalovirus Infection
Interventions
MaribavirDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical safety as measured by the recording of treatment emergent adverse eventsTime frame: 13 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California
UCLA Medical Center
Los Angeles, California
Loyola University
Maywood, Illinois
Tufts-New England Medical Center
Boston, Massachusetts
Wayne State Medical Center
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Memorial Sloan-Kettering Cancer Center
New York, New York
Duke Medical Center
Durham, North Carolina
Baylor University Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
University of Utah
Salt Lake City, Utah
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.